Cancer Science & Therapy

Feng Jiang

Feng Jiang, MD, PhD
Department of Pathology
University of Maryland, USA

Biography

Feng Jiang research has focused upon understanding molecular genetics aberrations and translating the resultant discoveries into clinical application for enhancing diagnosis and therapy of human malignancies. In the MCRCDP program. Dr. Jiang proposed to develop a noninvasive genetic test using an optimal panel of biomarkers for predicting recurrence of stage I lung cancer after surgery. There are three specific aims: 1) identify an optimal panel of genetic signatures that can be detected in sputum for accurately predicting lung cancer recurrence in an existing cohort of recurrent and nonrecurrent stage I lung cancer patients, 2) develop the genetic signatures as a robust and objective diagnostic test by labeling the genetic probes with quantum dots and counting signals with automation of fluorescent dot-counting, 3) prospectively validate the new diagnostic test for predicting recurrence in an independent cohort of stage I lung cancer patients by correlating the results with their clinical outcomes. The study will form the foundation for future multiple-center clinical trails designed to rapidly and widely adopt this prognostic approach in routine clinical practice. Its application in clinical settings will identify the patients at high risk for recurrence, potentially lead to more personalized treatment, and ultimately reduces lung cancer mortality.

Research Interest

To understand genomic and genetic aberrations lead to tumor formation, identify cancer genes, and translate the resultant new technologies and information into clinic for diagnosis and therapeutic interventions of cancer.